Qinjie Wu
Overview
Explore the profile of Qinjie Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu S, He T, Wang Y, Ma Y, Li W, Gong S, et al.
Theranostics
. 2024 Sep;
14(15):5984-5998.
PMID: 39346548
Neoadjuvant chemotherapy (NAC) has been recognized as an indispensable strategy for advanced malignancies. Nevertheless, the enhancement of overall patient survival in NAC recipients has encountered challenges due to the limited...
2.
Liang X, Li X, Wu R, He T, Liu F, Li L, et al.
Adv Sci (Weinh)
. 2024 May;
11(28):e2401377.
PMID: 38760901
Tumor-associated chronic inflammation severely restricts the efficacy of immunotherapy in cold tumors. Here, a programmable release hydrogel-based engineering scaffold with multi-stimulation and reactive oxygen species (ROS)-response (PHOENIX) is demonstrated to...
3.
Li Y, Zhou S, Wu Q, Gong C
Wiley Interdiscip Rev Nanomed Nanobiotechnol
. 2024 Mar;
16(1):e1938.
PMID: 38456346
CRISPR/Cas systems stand out because of simplicity, efficiency, and other superiorities, thus becoming attractive and brilliant gene-editing tools in biomedical field including cancer therapy. CRISPR/Cas systems bring promises for cancer...
4.
Luo R, Le H, Wu Q, Gong C
Small
. 2024 Mar;
20(30):e2312153.
PMID: 38441386
Gene therapy uses modern molecular biology methods to repair disease-causing genes. As a burgeoning therapeutic, it has been widely applied for cancer therapy. Since 1989, there have been numerous clinical...
5.
Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold
Li X, Liang X, Fu W, Luo R, Zhang M, Kou X, et al.
Bioact Mater
. 2024 Feb;
35:228-241.
PMID: 38333614
vaccine (ISV) is a promising immunotherapeutic tactic due to its complete tumoral antigenic repertoire. However, its efficiency is limited by extrinsic inevitable immunosuppression and intrinsic immunogenicity scarcity. To break this...
6.
Bai L, Yang J, Yu S, Xiang Z, Zeng Y, Shen M, et al.
Acta Pharm Sin B
. 2024 Feb;
14(2):821-835.
PMID: 38322329
Radiotherapy (RT) can potentially induce systemic immune responses by initiating immunogenic cell death (ICD) of tumor cells. However, RT-induced antitumor immunologic responses are sporadic and insufficient against cancer metastases. Herein,...
7.
Ma S, Li Y, Liu F, Wang X, Qin Z, Yang J, et al.
J Control Release
. 2024 Jan;
366:505-518.
PMID: 38184233
Vascular endothelial growth factor (VEGF) not only serves as an autocrine survival factor for tumor cells themselves, but also stimulates angiogenesis by paracrine pathway. Strategies targeting VEGF holds tremendous potential...
8.
Fu W, Li X, Li Y, Luo R, Ou C, Huang D, et al.
Biomaterials
. 2023 Dec;
305:122444.
PMID: 38142471
Immunogenicity improvement is a valuable strategy for tumor immunotherapy. However, immunosuppressive factors bestow tolerogenic phenotype on tumor-infiltrating DCs, which exhibit weak antigen presentation and strong anti-inflammatory cytokines secretion abilities, limiting...
9.
Gou Q, Liu L, Wang C, Wu Q, Sun L, Yang X, et al.
Colloids Surf B Biointerfaces
. 2023 Dec;
234:113679.
PMID: 38070370
No abstract available.
10.
Huang X, Li L, Ou C, Shen M, Li X, Zhang M, et al.
Adv Sci (Weinh)
. 2023 Oct;
10(35):e2303715.
PMID: 37875395
Coevolution of tumor cells and surrounding stroma results in protective protumoral environment, in which abundant vessel, stiff structure and immunosuppression promote each other, cooperatively incurring deterioration and treatment compromise. Reversing...